Ajouter à une liste

Instrument Inactif

Communiqués CURE PHAR Other OTC

Actions

US56088C1009

Cours en clôture Other OTC Autres places de cotation
- ^USD	-

Communiqués

07/06/17	Leading OTF Manufacturer CURE Pharmaceutical Comments on New Report Showing Exponential Growth in Thin Film Drug Manufacturing Market	GL
31/05/17	CURE Pharmaceutical and CannaKids Announce Research Collaboration with Technion-Israel Institute of Technology on Cancer-Fighting Cannabinoids	GL
24/05/17	CURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD.	GL
18/05/17	CURE Pharmaceutical Announces Crosslink Patent for Covering Company’s Proprietary CureFilm™ Drug Delivery Technology	GL
10/05/17	CURE Pharmaceutical Announces Entrance Into Booming Pharmaceutical Cannabis Industry	GL
09/05/17	CURE Pharmaceutical Strengthens Senior Leadership Team with Appointment of Industry Veteran Richard Serbin as Head of Global Corporate Development	GL
03/05/17	CURE Pharmaceutical Adds Industry Veteran, Anti-Aging Specialist and Medicinal Cannabis Supporter, Alan Einstein, to Its Board of Directors	GL
29/03/17	CURE Pharmaceutical Announces Development and Licensing Deal with Redbarn Pet Products	GL
27/03/17	CURE Pharmaceutical To Exhibit at the 8th Global Drug Delivery & Formulation Summit	GL
23/03/17	CURE Pharmaceutical Welcomes Researcher and Innovator in Pediatric Medicine Michael Neely to Advisory Board	GL
21/03/17	CURE Pharmaceutical Announces Product Development and Licensing Deal with Diverse International Pharmaceutical Company Meroven, Ltd.	GL
16/03/17	CURE Pharmaceutical To Exhibit at INTERPHEX 2017 in New York City	GL
15/03/17	Industry Veteran Jessica Rousset Joins CURE Pharmaceutical As Chief Business Officer	GL
13/03/17	CURE Pharmaceutical Announces US Patent Allowances for Its Oral Thin Film Technology For Manufacture and Use in Pet Products	GL
06/03/17	CURE Pharmaceutical Announces Research Collaboration with CannaKids to Develop Cannabinoid and Terpene Molecules Using Cure’s Proprietary Delivery Technologies	GL
27/01/17	CURE Pharmaceutical Welcomes Industry Veteran Richard Serbin to its Advisory Board	GL
24/01/17	CURE Pharmaceutical Moves to OTCQB Exchange	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Espace mes listes

Palmarès

Suite du Palmarès

Palmarès

Suite du Palmarès

Devises / Forex

Matières Premières

Cryptomonnaies

Taux d'Intérêts

Tous les transcripts sur plus de 9000 sociétés, le jour de leur publication !

Débloquez-les Maintenant !

Débloquez-les Maintenant !